Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is projected to experience substantial revenue growth, with an anticipated increase of over 20% annually through 2026, driven by commercial sales of established products and recent launches. The company's total income from royalty agreements surged to $28.5 million in 2024, a significant rise from $4.8 million in 2023, indicating robust growth in its royalty-based income streams. Continued expansion of its royalty aggregate business and the potential contributions from earlier-stage assets, including milestone payments, further support a positive financial outlook for XOMA.

Bears say

XOMA Royalty Corp has experienced significant volatility in its revenues and net earnings, primarily due to the unpredictable nature of the international biotech market, suggesting an inherent sensitivity to economic fluctuations and policy changes. The company faces challenges such as potential setbacks in clinical trials and funding shortages, which could severely hinder its ability to progress drug candidates and adversely impact operational sustainability. Additionally, recent stock performance indicates a decline from pandemic-era highs, exacerbated by broader market downturns in the biotechnology sector, raising concerns about investor confidence and long-term growth prospects.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.